Provision of informed consent before any study-specific procedures.
Histologic confirmation of invasive breast cancer.
Plans for the administration of neoadjuvant chemotherapy.
Not currently pregnant during the study
You may not be if
Severe gastrointestinal disorder
Current use of statins or fibrates for any time during the 3 months before the study
Proven hypersensitivity to statins
Currently on medication for hypercholesterolemia
Strong Cytochrome P450 3A4 (abbreviated CYP3A4) (e.g., clarithromycin, HIV protease inhibitors, and itraconazole), given potential interactions with statins
Renal impairment with a creatinine \> 1.4 mg/dl
Hepatic impairment: Aspartate transaminase (AST)/(SGOT), Alanine Transaminase (ALT)/(SGPT) ≥ 2.5 x upper limit of the normal range (ULN), OR Total bilirubin ≥ 1.5 x ULN (subjects with Gilbert's syndrome can have bilirubin of up to 1.5 x ULN), OR Alkaline phosphatase \> 2.5 x ULN
Central nervous system (CNS) diseases and major psychiatric diseases or inability to comply with the protocol procedures
Active infections
Cardiac failure, class I-IV
Current anticoagulant or antiplatelet aggregation therapy
Current lactation
Clareo Health | Efficacy of Statin Addition to Neoadjuvant Chemotherapy Protocols for Breast Cancer
